Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.

The Journal of antimicrobial chemotherapy - 1 May 2007

Delaney William E

Abstract excerpt

Most chronic hepatitis B patients do not undergo a curative response to interferon-alpha or nucleoside/nucleotide-based regimens and require long-term therapy. Long-term safety, efficacy and resistance profiles of hepatitis B virus (HBV) drugs are therefore crucial issues for patient management....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Organophosphonates

Share to Phenotype

Source

Identifiers

PMID: 17332007
DOI: 10.1093/jac/dkl551

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17332007-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.PMID 17332007Read ↗

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.Semantic proximity Read ↗

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semantic proximity Read ↗

[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].Semantic proximity Read ↗

Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.Semantic proximity Read ↗

Long‐term therapy for chronic hepatitis B : Hepatitis B virus DNA suppression leading to cirrhosis reversalSemantic proximity Read ↗

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.Semantic proximity Read ↗

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.